Μετάβαση στο περιεχόμενο

ΕτικέταSarepta Therapeutics

Sarepta Therapeutics Signs Long-term Strategic Investment and License Agreements with Lacerta Therapeutics, Gaining Rights to Multiple CNS-targeted Gene Therapy programs and Access to Important Gene Therapy Talent and Tools

Sarepta expands its presence in gene therapy and broadens its reach with license to up to three new CNS-targeted gene therapy programs, including exclusive rights to Lacerta’s  gene therapy candidate for … Continue Reading Sarepta Therapeutics Signs Long-term Strategic Investment and License Agreements with Lacerta Therapeutics, Gaining Rights to Multiple CNS-targeted Gene Therapy programs and Access to Important Gene Therapy Talent and Tools

Sarepta Halts Muscular Dystrophy Trial Because of Production Issues

  The U.S. Food and Drug Administration (FDA) notified Cambridge, Massachusetts-based Sarepta Therapeutics that its Phase I/IIa Micro-Dystrophin Gene Therapy Trial for Duchenne muscular dystrophy (DMD) has been placed on a clinical hold because of contamination … Continue Reading Sarepta Halts Muscular Dystrophy Trial Because of Production Issues

Biotech Manufacturing is Booming with Growth of Biologics and Gene Therapies

Manufacturing is the non-glamorous side of biopharma, although its impact on the economy shouldn’t be underestimated. For example, a recent report published by TEConomy and BIO titled, “Investment, Innovation and Job Creation in a Growing U.S. … Continue Reading Biotech Manufacturing is Booming with Growth of Biologics and Gene Therapies